Announced Date: 2025-10-31 (October 31, 2025)
Asset Name: MWN105
Licensor (Seller): Shanghai Minwei Biotech, subsidiary of Lepu Healthcare (China)
Licensee (Buyer): Sidera Bio (Denmark)
.
Asset Modality: Peptides
Asset Target: GLP-1/GIP/FGF21 Agonist
Potential Indication: Diabetes, Obesity
Current Stage: Phase II in China
.
Scope of Authority:
Sidera will obtain exclusive rights to develop and commercialize them globally other than Greater China (Mainland China, Hong Kong, Macau and Taiwan).
.
Payment Detail:
Minwei Biotech will receive:
(i) upfront and near term payment of USD$35 million,
(ii) receive approximately 9.99% of the equity of Sidera,
(iii) milestones payments of up to USD$1.01 billion.
(iv) tiered royalties on net sales.
.
Link:
1224781648.PDF (cninfo.com.cn)
.
Note:
Chinese Name of Minwei Biotech, 民为生物 （乐普）
